Liver transplantation: an update 2007

Purpose of review Recent attention in liver transplantation has focused on equity in organ allocation and management of posttransplant complications. Recent findings Adoption of the model for end-stage liver disease for liver allocation has been successful in implementing a system based on medical urgency rather than waiting time. Refinements are being studied in improving the prediction of mortality and improving transplant benefit by balancing pretransplant mortality and posttransplant survival. Emerging literature is examining expansion of the current criteria for transplantation of hepatocellular carcinoma and the role of neoadjuvant therapy. Chronic renal dysfunction after liver transplantation is a source of considerable morbidity. Nephron-sparing immunosuppression regimens are emerging with encouraging results. Hepatitis C virus infection is difficult to differentiate histologically from rejection, although newer markers are being developed. Antiviral and immunosuppressive strategies for reducing the severity of hepatitis C virus recurrence are discussed. Alcohol relapse is common after liver transplant in alcoholic liver disease patients and can lead to worse outcomes. Summary Organ allocation tends to evolve under the model for end-stage liver disease with a focus on maximizing transplant benefit. Hepatitis C virus, hepatocellular carcinoma, chronic renal dysfunction and alcohol relapse are major challenges, and continued research in these areas will undoubtedly lead to better outcomes for transplant recipients.

[1]  M. Abecassis,et al.  Improvement in survival associated with adult-to-adult living donor liver transplantation. , 2007, Gastroenterology.

[2]  R. Wiesner,et al.  Differential Effects of Donor Age in Liver Transplant Recipients Infected With Hepatitis B, Hepatitis C and Without Viral Hepatitis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  H. Nivet,et al.  Early Pulse Pressure and Low‐Grade Proteinuria as Independent Long‐Term Risk Factors for New‐Onset Diabetes Mellitus After Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  P. Nyckowski,et al.  Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. , 2003, Transplantation proceedings.

[5]  R. Weber,et al.  Are HIV-infected patients candidates for liver transplantation? , 2008, Journal of hepatology.

[6]  Zhao-You Tang,et al.  Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[7]  H. Feucht Significance of donor-specific antibodies in acute rejection. , 2005, Transplantation proceedings.

[8]  M. Orloff,et al.  Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post‐liver transplant biopsies , 2006, Clinical transplantation.

[9]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[10]  M. Stegall,et al.  Chronic renal dysfunction late after liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  J. Roberts,et al.  Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  I. Bilbao,et al.  Liver transplantation in HIV-HCV coinfected patients: a case-control study. , 2007, Transplantation.

[13]  D. Douglas,et al.  Natural history of hepatitis C following liver transplantation , 2004, Current opinion in infectious diseases.

[14]  D. Nelson,et al.  Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  M. Berenguer What determines the natural history of recurrent hepatitis C after liver transplantation? , 2005, Journal of hepatology.

[16]  D. Fine,et al.  Independent risk factors and natural history of renal dysfunction in liver transplant recipients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  B. Spiegel,et al.  A comparison of liver transplantation outcomes in the pre‐ vs. post‐MELD eras , 2005, Alimentary pharmacology & therapeutics.

[18]  N. Terrault Treatment of recurrent hepatitis C in liver transplant recipients. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  J. Palefsky,et al.  Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study1 , 2003, Transplantation.

[20]  Mohamed Rela,et al.  Pretransplant MELD score and post liver transplantation survival in the UK and Ireland , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  U. Neumann,et al.  Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: A single‐center study of 289 patients , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[23]  U. Neumann,et al.  Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up , 2004, Transplantation.

[24]  A. Lok,et al.  Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  J. Barkun,et al.  Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  M. Haberal,et al.  Right hepatic lobe donation: impact on donor quality of life. , 2007, Transplantation proceedings.

[27]  R. Fisher,et al.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death , 2004, Hepatology.

[28]  R. Striker,et al.  EFFECT OF ANTIMETABOLITE IMMUNOSUPPRESSANTS ON FLAVIVIRIDAE, INCLUDING HEPATITIS C VIRUS , 2004, Transplantation.

[29]  J. Torre-Cisneros,et al.  Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease , 2006, AIDS.

[30]  D. Seehofer,et al.  Long‐term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  A. Dhillon,et al.  Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[33]  T. Pfammatter,et al.  Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence‐Based Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  G. Loss,et al.  Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  J. Roberts,et al.  Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. , 2000, Transplantation.

[36]  G. Klintmalm,et al.  A Comparison of Tacrolimus and Cyclosporine in Liver Transplantation: Effects on Renal Function and Cardiovascular Risk Status , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  S. Roayaie,et al.  Treatment of HCC in Patients Awaiting Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[39]  E. Schiff,et al.  Outcomes After Orthotopic Liver Transplantation in 15 HIV-Infected Patients , 2007, Transplantation.

[40]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[41]  K. Reddy,et al.  Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. , 1998, Transplantation.

[42]  A. Demetris,et al.  Survival of Liver Transplant Patients Coinfected with HIV and HCV Is Adversely Impacted by Recurrent Hepatitis C , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[43]  R. Fisher,et al.  Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[44]  Nick Murphy,et al.  Self-Organizing Maps Can Determine Outcome and Match Recipients and Donors at Orthotopic Liver Transplantation , 2005, Transplantation.

[45]  C. Kin,et al.  Extended-donor criteria liver allografts. , 2006, Seminars in liver disease.

[46]  I. Horwitz,et al.  Waitlist Mortality Decreases with Increased Use of Extended Criteria Donor Liver Grafts at Adult Liver Transplant Centers , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  Sammy Saab,et al.  Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation , 2005, Hepatology.

[48]  J. Carter,et al.  Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[49]  P. Neuhaus,et al.  Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[50]  G. Gerken,et al.  Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. , 2004, Transplantation proceedings.

[51]  M. G. Krukemeyer,et al.  C4d in Acute Rejection After Liver Transplantation—A Valuable Tool in Differential Diagnosis to Hepatitis C Recurrence , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  G. Testa,et al.  Right‐liver living donor transplantation for decompensated end‐stage liver disease , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[53]  J. Saric,et al.  Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal , 2002, Clinical transplantation.

[54]  R. Striker,et al.  Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B , 2007, Hepatology.

[55]  J. Albrecht,et al.  Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. , 2003, Gastroenterology.

[56]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[57]  M. Navasa,et al.  Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. , 2006, Gastroenterology.

[58]  D. Streblow,et al.  Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. , 1998, Virology.

[59]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[60]  T. Davern,et al.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[61]  M. De Luca,et al.  Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. , 2007, Journal of hepatology.

[62]  R. Gish,et al.  A model to predict severe HCV‐related disease following liver transplantation , 2003, Hepatology.

[63]  M. Peters,et al.  HIV and liver disease forum: Conference proceedings , 2007, Hepatology.

[64]  J. Trotter,et al.  Expanding donor options: marginal, living, and split donors. , 2007, Clinics in liver disease.

[65]  W. Jaschke,et al.  Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[66]  I. McGilvray,et al.  Reduced Mortality with Right‐Lobe Living Donor Compared to Deceased‐Donor Liver Transplantation When Analyzed from the Time of Listing , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  C. Sabin,et al.  Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[68]  D. Theriaque,et al.  One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[69]  J. Prieto,et al.  Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[70]  H. Yoo,et al.  Short‐term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[71]  S. Biggins,et al.  Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[72]  A. Mclellan,et al.  Interpreting the significance of drinking by alcohol‐dependent liver transplant patients: Fostering candor is the key to recovery , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[73]  X. Forns,et al.  Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. , 2007, Gastroenterology.

[74]  R. Wiesner,et al.  Predictors of patient and graft survival following liver transplantation for hepatitis C , 1998, Hepatology.

[75]  C. Trépo,et al.  Histological Benefit of Retreatment by Pegylated Interferon Alfa‐2b and Ribavirin in Patients with Recurrent Hepatitis C Virus Infection Posttransplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[76]  T. Gonwa,et al.  Continued Influence of Preoperative Renal Function on Outcome of Orthotopic Liver Transplant (OLTX) in the US: Where Will MELD Lead Us? , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[77]  A. Burroughs,et al.  Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation , 2003, Transplantation.

[78]  R. Wiesner,et al.  Results of the first year of the new liver allocation plan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[79]  U. Neumann,et al.  Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. , 2005, Transplantation proceedings.

[80]  N. Terrault,et al.  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[81]  W. Chapman,et al.  Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. , 2006, Journal of the American College of Surgeons.

[82]  B. Gillespie,et al.  Severe Psychiatric Problems in Right Hepatic Lobe Donors for Living Donor Liver Transplantation , 2007, Transplantation.

[83]  A. Lok,et al.  Recipient Morbidity After Living and Deceased Donor Liver Transplantation: Findings from the A2ALL Retrospective Cohort Study† , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[84]  J. Everhart,et al.  Outcomes of donor evaluation in adult‐to‐adult living donor liver transplantation , 2007, Hepatology.

[85]  L. Magder,et al.  Impact of Human Immunodeficiency Virus on Survival After Liver Transplantation: Analysis of United Network for Organ Sharing Database , 2008, Transplantation.

[86]  M. Dew,et al.  Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[87]  M. Hudson,et al.  Mycophenolate mofetil monotherapy in liver transplantation , 2001, The Lancet.

[88]  K. Saeian,et al.  MELD Score Does Not Discriminate Against Patients with Hepatic Encephalopathy , 2005, Digestive Diseases and Sciences.

[89]  R. Wiesner,et al.  Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[90]  G. Otto,et al.  Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. , 2007, Transplantation proceedings.

[91]  J. Barkun,et al.  EFFICACY OF MYCOPHENOLATE MOFETIL COMBINED WITH VERY LOW‐DOSE CYCLOSPORINE MICROEMULSION IN LONG‐TERM LIVER‐TRANSPLANT PATIENTS WITH RENAL DYSFUNCTION , 2003, Transplantation.

[92]  E. Schiff,et al.  Orthotopic liver transplantation in patients with human immunodeficiency virus and end‐stage liver disease , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[93]  Ryutaro Hirose,et al.  Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis , 2008, Hepatology.

[94]  J. Emond,et al.  Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[95]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[96]  M. Choi,et al.  Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. , 2006, World journal of gastroenterology.

[97]  J. Zamora,et al.  Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta‐analysis , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[98]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[99]  K. Boudjema,et al.  C4d: a marker for hepatic transplant rejection. , 2006, Transplantation proceedings.

[100]  D. Samuel,et al.  Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus , 2007, Hepatology.

[101]  T. Powles,et al.  Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. , 2008, World journal of gastroenterology.

[102]  N. Heaton,et al.  Survival of human immunodeficiency virus-infected liver transplant recipients. , 2003, The Journal of infectious diseases.

[103]  Mark J. Thomas,et al.  A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[104]  V. Paradis,et al.  Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. , 2006, AJR. American journal of roentgenology.

[105]  G. Silberhumer,et al.  Combination of Extended Donor Criteria and Changes in the Model for End-Stage Liver Disease Score Predict Patient Survival and Primary Dysfunction in Liver Transplantation: A Retrospective Analysis , 2007, Transplantation.

[106]  G. Otto,et al.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[107]  G. Klintmalm,et al.  Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[108]  P. Waldenberger,et al.  Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[109]  A. Jain,et al.  Living‐Donor Liver Transplantation in the United States: Identifying Donors at Risk for Perioperative Complications , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[110]  D. Samuel,et al.  Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study , 2007, Clinical pharmacokinetics.

[111]  T. Pruett,et al.  Donor Factors Predicting Recipient Survival After Liver Retransplantation: The Retransplant Donor Risk Index , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[112]  A. Lok,et al.  Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[113]  P. Marik,et al.  The course of type 1 hepato-renal syndrome post liver transplantation. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[114]  P Neuhaus,et al.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.

[115]  A. Moya,et al.  Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipients , 2002, Hepatology.

[116]  E. Edwards,et al.  Utilization of Extended Donor Criteria Liver Allograft: Is the Elevated Risk of Failure Independent of the Model for End-Stage Liver Disease Score of the Recipient? , 2006, Transplantation.

[117]  C. von Kalle,et al.  Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib® versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794] , 2008, BMC Cancer.

[118]  M. Manns,et al.  Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. , 2000, Transplantation.

[119]  G. Everson,et al.  Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy , 2005, Hepatology.

[120]  T. Therneau,et al.  Evidence-based incorporation of serum sodium concentration into MELD. , 2006, Gastroenterology.

[121]  J. Llovet,et al.  Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation , 2004, Hepatology.

[122]  J. Bragg-Gresham,et al.  Characteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  K. Shimotohno,et al.  Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes , 2003, Hepatology.

[124]  J. Scheele,et al.  Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. , 2005, International immunopharmacology.

[125]  U. Christians,et al.  Cyclosporine Pharmacokinetics and Dosing Modifications in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients , 2005, Transplantation.

[126]  M. Katze,et al.  Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. , 2006, Gastroenterology.

[127]  K. Richardson,et al.  Interferon‐Based Combination Anti‐Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[128]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[129]  P. Angeli,et al.  Intention‐to‐Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[130]  C. Broelsch,et al.  Psychological strain in urgent indications for living donor liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[131]  S. Hossain,et al.  Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[132]  I. Ng,et al.  Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma , 2007, The British journal of surgery.

[133]  J. Dumortier,et al.  Impact of adult‐to‐adult living donor liver transplantation on access to transplantation and patients' survival: An 8‐year single‐center experience , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[134]  F. Roudot-thoraval,et al.  Impact of UCSF criteria according to pre‐ and post‐OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[135]  L. Mariani,et al.  Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study , 2004, Annals of surgery.

[136]  G. Klintmalm,et al.  Impact of tacrolimus versus cyclosporine in hepatitis C virus‐infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[137]  M. Mihatsch,et al.  THE EFFECT OF CYCLOSPORINE ON THE PROGRESSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION TRANSMITTED BY TRANSPLANTATION–DATA ON FOUR CASES AND REVIEW OF THE LITERATURE , 1993, Transplantation.

[138]  M. Vogel,et al.  Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort , 2007, AIDS.

[139]  Robert S Brown,et al.  Live donors in liver transplantation. , 2008, Gastroenterology.

[140]  Peter Bacchetti,et al.  Serum sodium predicts mortality in patients listed for liver transplantation , 2005, Hepatology.

[141]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[142]  J. Emond,et al.  Donor morbidity after living donation for liver transplantation. , 2008, Gastroenterology.

[143]  A. Tannapfel,et al.  Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. , 2005, International immunopharmacology.